相关实验视频
Updated: Jul 15, 2026

11:21
Robotic Ablation of Atrial Fibrillation
Published on: May 29, 2015
19.6K
关于机器人穿皮冠状动脉干预的最新研究进展的叙述性综述
1Department of Clinical Medicine, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
Journal of geriatric cardiology : JGC
|September 23, 2024
概括
机器人穿皮冠状动脉干预 (R-PCI) 为心脏病专家提供了减少的辐射和骨科风险. 虽然短期数据显示成功,但需要长期随机试验才能广泛采用.
科学领域:
- 干预心脏病学 干预心脏病学
- 医疗机器人 医疗机器人
- 心血管干预 心血管干预
背景情况:
- 机器人穿皮冠状动脉干预 (R-PCI) 在心脏手术期间使用机器人系统进行导管和导线操纵.
- 目前来自队列研究的证据表明,R-PCI的短期安全性和高技术成功率.
- 对于干预心脏病学家来说,R-PCI具有潜在的好处,包括减少辐射暴露和减少骨科损伤的风险.
研究的目的:
- 为R-PCI审查机器人技术的最新进展.
- 讨论R-PCI的当前临床应用和未来潜力.
- 在干预性心脏病学中确定R-PCI实施的挑战和机会.
主要方法:
- 这篇叙事综述综合了机器人辅助心脏干预的最新发展.
- 专注于技术创新及其对R-PCI程序的影响.
- 文献搜索包括关于R-PCI安全性,有效性和未来方向的研究.
主要成果:
- 在队列研究中,R-PCI显示出有希望的短期安全性和有效性.
- 针对复杂冠状动脉病变的远程支架应用显示了R-PCI的重大未来潜力.
- 关键的挑战包括程序延迟,患者管理和特定设备和病变类型的限制.
结论:
- R-PCI提供了实质性的好处,但需要长期的随机化数据才能融入标准实践.
- 实验室工作流程,3D建模和控制算法的未来进展将增强R-PCI的能力.
- 解决目前的局限性对于实现R-PCI在心血管干预中的全球潜力至关重要.
相关概念视频
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...

